<DOC>
	<DOCNO>NCT00521092</DOCNO>
	<brief_summary>Sunitinib malate may stop growth tumor cell block enzymes need cell growth block blood flow tumor . This phase II trial study side effect well sunitinib malate work treat patient Kaposi sarcoma .</brief_summary>
	<brief_title>Sunitinib Malate Treating East African Patients With Kaposi Sarcoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine clinical response sunitinib malate patient Kaposi sarcoma ( KS ) Uganda Kenya . II . Compare clinical response rate endemic versus epidemic ( AIDS ) KS . III . Determine safety tolerability sunitinib malate patient endemic epidemic ( AIDS ) KS . SECONDARY OBJECTIVES : I Monitor impact sunitinib malate underlie HIV-1 Kaposi sarcoma-associated herpesvirus ( KSHV ) viral infection ( HIV-1 plasma RNA KSHV cell-associated DNA ) . II . Evaluate morphological change KS lesion treatment . III . Determine pharmacokinetic profile sunitinib malate patient KS . IV Evaluate KSHV gene expression endemic epidemic KS lesion patient Uganda Kenya . OUTLINE : This multicenter study . Patients stratify accord HIV-serostatus ( endemic [ HIV-seronegative ] v epidemic [ HIV-seropositive/AIDS ] kaposi sarcoma ) . Patients receive oral sunitinib malate 50 mg daily 4 week . Treatment repeat every 6 week absence disease progression unacceptable toxicity . Patients undergo tumor tissue blood sample collection periodically correlative pharmacokinetic study . Samples analyze CD4 lymphocyte count , HIV-1 plasma RNA level , KSHV specific antibody , expression pattern KSHV vitro vivo , expression latently versus lytically express gene tumor tissue , plasma concentration sunitinib malate active metabolite , SU12662 . After completion study treatment , patient follow every 6 week .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>ECOG performance status 01 Documented HIVserostatus [ HIVseronegative ( endemic KS ) HIVseropositive ( epidemic/AIDS KS ) ] No symptomatic organ involvement , visceral crisis , lifethreatening disease ( e.g. , extensive symptomatic pulmonary disease reticuloendothelial system/hepatic involvement ) aggressive double tripledrug combination chemotherapy urgent cytoreduction indicate ( i.e. , doxorubicin hydrochloride , bleomycin , vinblastine [ ABV ] , BV , AV ) Histologically confirm Kaposi sarcoma Platelet count &gt; 75,000/uL Life expectancy &gt; = 24 week Absolute granulocyte count &gt; 1,000/uL Hemoglobin &gt; 8.0 g/dL OR hematocrit &gt; 24 % Serum creatinine = &lt; 2.0 mg/dL AST &lt; 3 time normal Fertile patient must use effective contraception Normal clinical cardiac examination normotensive ( systolic diastolic BP &lt; 140/90 mm Hg ) document least two occasion prior enrollment Normal ECG include QTc interval &lt; 500 msec Normal echocardiogram prior enrollment ( feasibly possible ) Must able swallow study medication No acute infection [ Patients chronic infection ( e.g. , malaria , tuberculosis , parasitic infection , hepatitis B C ) may active treatment allow provide eligibility criterion meet ] At least 60 day since prior local treatment modality ( e.g. , resection , cryosurgery , radiotherapy , intralesional therapy ) AND treated lesion must clearly progress follow therapy lesion use index lesion No prior systemic anticancer therapy Kaposi sarcoma Concurrent antiretroviral therapy require HIVseropositive patient ( Patient must stable regimen 8 week prior study enrollmentAn exception may make patient exhausted intolerant available regimen ) No concurrent systemic anticancer therapy Patient reside Uganda Kenya , East Africa Pregnant nursing Baseline diarrhea &gt; = grade 2 CTCAE Uncontrolled intercurrent illness include , limited , follow : Ongoing acute active infection Symptomatic congestive heart failure ( NYHA class III IV heart disease ) Unstable angina pectoris Uncontrolled intercurrent illness include , limited , follow : 1 ) Cardiac arrhythmia ( i.e. , history serious ventricular arrhythmia , ventricular fibrillation , ventricular tachycardia &gt; = 3 beat row OR QTc &gt; = 500 msec ) 2 ) Psychiatric illness social situation would limit compliance study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Treatment Experienced</keyword>
</DOC>